
    
      This study is a prospective, randomized controlled trial, which the subjects were severe
      sepstic patients for selecting Meropenem as antimicrobial drugs. The experimental and control
      group were used different administration of Meropenem through monitoring the Meropenem plasma
      concentration and clinical data, eventually demonstrate the effecacy and safety of Meropenem
      in patients with severe infection and optimize the best clinical practice for antimicrobial
      agents.
    
  